EGFR and C-met fibronectin type III domain binding molecules
US12304939B2 · kind B2 · utility
0Cited by
9References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 12, 2021 |
| Grant date | May 20, 2025 |
| Priority date | — |
| Expiry date | Feb 13, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/70
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.